The UK Competition and Markets Authority (CMA) is investigating Vifor Pharma over concerns of potential anti-competitive practices, focusing on the availability and affordability of essential anaemia treatments.

The U.S. government is set to propose drug price cuts for the pharmaceutical industry in a move already anticipated by drugmakers. This initiative is part of a broader effort to reduce healthcare costs, with the government leveraging its Medicare program to negotiate prices directly with pharmaceutical companies for certain expensive medications.

Stephen J Ubl, president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA) will join Fierce for a Fireside chat. Ubl is known as a leading health care advocate and policy expert, and represents the U.S. biopharmaceutical industry, which employs more than 800,000 Americans and invests more than $100 billion each year in R&D.